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INTRODUCTION
Limb girdle muscular dystrophy (LGMD) is a clinically and ge-
netically heterogeneous group of disorders characterized by 
progressive weakness of the pelvic and shoulder girdle mus-
cles. Currently, eight autosomal dominant LGMDs (LGMD1) 
and 22 autosomal recessive LGMDs (LGMD2) have been iden-
tified. LGMD2A is the most prevalent form in many European 
countries.1,2 LGMD2A is caused by mutations in the CAPN3 
gene (MIM#114240) on chromosome 15q15.1. Calpain-3, en-
coded by the CAPN3 gene, is a muscle-specific member of the 
calpain superfamily of calcium-activated neutral proteases. 
Calpain-3 is associated with regulatory processes such as apop-
tosis, muscle cell differentiation, sarcomere formation, muscle 
remodeling, and regulation of the cytoskeleton. However, the 
pathogenesis of calpainopathy remains a subject of discussion.
The typical clinical presentation of LGMD2A includes pro-
gressive proximal muscle weakness, ankle contracture, and 
winged scapula. However, calpainopathy, caused by CAPN3 
mutations, reveals not only LGMD2A phenotypes but also vari-
able clinical phenotypes including pseudometabolic myopa-
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thy, eosinophilic myositis, and asymptomatic hyperCKemia.3-6 
There has been only one small case series of calpainopathy in 
Korea.7 To identify the characteristics of Korean calpainopathy, 
we analyzed mutational, clinical, and pathological spectra in 
Korean patients with CAPN3 mutations.
MATERIALS AND METHODS
Subjects
We reviewed our myopathy biobank, which contained 505 
muscle and 448 blood samples taken from 896 myopathy pa-
tients between March 2004 and August 2011. Firstly, we found 
four patients from three unrelated families (F1, F2, and F3) who 
had been previously diagnosed with calpainopathy. F1 and F2 
patients were diagnosed with calpainopathy via direct se-
quencing of CAPN3. Two affected members of the F3 family 
were confirmed via targeted sequencing for 16 LGMD-related 
genes (CAPN3, CAV3, DYSF, FKRP, FKTN, LMNA, MYOT, 
POMGT1, POMT1, POMT2, SGCA, SGCB, SGCD, SGCG, TCAP, 
and TRIM32). Secondly, we screened the biobank based on 
the following inclusion criteria: 1) genetically unconfirmed 
LGMD or hyperCKemia, 2) autosomal recessive or sporadic in-
heritance, and 3) serum creatine kinase (CK) levels of more 
than threefold above the upper limit of normal. We selected 
51 myopathy patients and performed targeted sequencing of 
CAPN3. In this way, we identified CAPN3 mutations in nine 
patients from seven unrelated families (F4, F5, F6, F7, F8, F9, 
and F10). Then, we analyzed mutational, clinical, and patho-
logical data in 13 calpainopathy patients from ten unrelated 
families (Fig. 1A). The research protocol was approved by the 
Institutional Review Board of Gangnam Severance Hospital, 
Korea. All participants were previously required to sign an in-
formed consent document for mutational analysis.
Targeted sequencing
Genomic DNA from muscle or blood from 51 myopathy patie-
nts was extracted with Qiagen DNeasy blood & tissue kits (Qia-
gen, Valencia, CA, USA). For mutation analysis, the CAPN3 
gene was enriched via hybridization capture. The target region 
included all 24 coding exons and flanking introns of the CAPN3 
gene. The captured library was sequenced using an Illumina 
Hiseq2500 platform with the 2×150 bp paired-end read mod-
ule. All samples were pooled into a part of a single lane on a sin-
gle flow cell and sequenced together. A 6-bp index sequence 
(Illumina, San Diego, CA, USA) and a 6-bp in-house barcode 
sequence were used to differentiate between samples. We 
achieved 497.19× mean (or 471.94× median) coverage for all 
samples. Exonic coverage of the CAPN3 gene at 20× or more 
was plotted in a standard boxplot. For 99.90% of target regions, 
capture was at least 20× coverage. Almost 99.98% of regions 
were captured with at least 10× coverage.
Variant analysis
From HiSeq2500 raw data, sequencing data of all samples were 
sorted by index and barcode sequences. Sorted fastq files were 
aligned to the hg19 reference genome with the Burrows-Whe-
eler Aligner (ver. 0.7.5a) algorithm.8 Output SAM files were con-
verted to BAM files and sorted with SAMtools (ver. 0.1.18).9 
Duplicate removal was performed with MarkDuplicates in 
Picard tools (ver. 1.95). Realignment around known indel sites 
and base quality score recalibration were performed with the 
genome analysis toolkit (GATK; ver. 2.6–5) to create the final 
BAM files.10
Variants were called with the GATK v2.6 Unified Genotyper 
algorithm.11,12 Called variants were filtered based on the follow-
ing criteria: 1) loci depth ≥10, variant frequency ≥0.5 and 2) loci 
depth ≥20, variant frequency ≥0.25. Filtered variants were anno-
tated with Annovar (ver. 2013-06-21) using RefGene, dbSNP 
135, and the 1000 Genomes Project SNP (2012 April release) of 
the Asian population and all-population databases. Among 
called variants, only non-synonymous single nucleotide vari-
ants, frameshift indels, and splicing-site variants were chosen. 
Polymorphisms in Korean populations (n=276) were filtered 
out. Variants with low functional scores in Polyphen2 (ver. 2.2.2) 
were considered to be benign mutations and discarded.13 All 
selected variants were validated by Sanger sequencing.
Clinical assessment
Clinical data included sex; age at symptom onset; family his-
Table 1. CAPN3 Mutations in Korean Patients with Calpainopathy
Location Mutation* Putative effect Affected family References
Exon 5 c.706G>A p.A236T F4 Krahn, et al.5
Exon 11 c.1468C>T p.R490W F3 Fanin, et al.15
Intron 11 c.1524+1G>T Aberrant splicing F7 Novel
Exon 15 c.1789_1790insA Frameshift F4, F7, F8 Novel
Exon 15 c.1795dupA Frameshift F1, F2 Chae, et al.16
Intron 18 c.2050+1G>A Aberrant splicing F3 Chae, et al.16
Exon 20 c.2120A>G p.D707G F1, F5, F6, F8, F9 Chae, et al.16
Intron 20 c.2184+1G>T Aberrant splicing F10 Novel
Exon 23 c.2384C>T p.A795V F5 Novel
*Mutation was assigned according to the CAPN3 (NM_000070) mRNA sequences.
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tory; initial diagnosis; and presence of winged scapula, lordo-
sis, joint contracture, motor weakness, and muscle wasting. To 
determine physical disability, we used a Gardner-Medwin and 
Walton (GMW) scale that had been previously assigned to 
each patients: grade 0, all normal activities and hyperCKemia; 
grade 1, normal gait, unable to run freely; grade 2, abnormal 
gait; grade 3, muscle weakness, climbing stairs with support; 
grade 4, positive Gower sign; grade 5, unable to rise from floor; 
grade 6, unable to climb stairs; grade 7, unable to get up from 
chairs; grade 8, unable to walk independently; grade 9, unable 
to eat, drink, or sit without support.14 Laboratory findings in-
cluded serum CK level, nerve conduction study, needle elec-
tromyography, electrocardiography, and echocardiography. 
Serum CK level was expressed as fold over the upper limit of 
normal values according to the local reference range in 12 pa-
tients, excluding F9 patients. Nerve conduction studies and 
needle electromyography were performed in all 13 patients. 
Electrocardiography was performed in eight patients (F3a, 
F3b, F4, F5a, F5b, F5c, F6, and F8). Echocardiograms were per-
formed in F5a and F5b patients.
Pathological assessment
Muscle specimens were obtained for nine patients, taken from 
the vastus lateralis (F1, F4, F5c, F7, F9, and F10) and the biceps 
brachii (F5b, F6, and F8). Frozen muscle sections (5-μm thick-
ness) from all muscle specimens were stained with hematoxy-
lin and eosin, modified Gomori trichrome, and reduced nico-
tinamide adenine dinucleotide-tetrazolium reductase. Protein 
analysis was performed in seven patients (F4, F5b, F6, F7, F8, 
F9, and F10). Western blots used antibodies against calpain-3 
(Novocastra, NewcastleuponTyne, UK). Muscle specimens 
were also analyzed by immunohistochemistry using antibod-
ies against the C-terminus of dystrophin (Leica Microsystems, 
Newcastle upon Tyne, UK), the rod domain of dystrophin (Lei-
ca Microsystems), the N-terminus of dystrophin (Leica Micro-
systems), dysferlin (Leica Microsystems), α-sarcoglycan (Leica 
Microsystems), β-sarcoglycan (Leica Microsystems), γ-sarco-
glycan (Leica Microsystems), δ-sarcoglycan (Leica Microsys-
tems), α-dystroglycan (Millipore, Billerica, MA, USA), and ca-
veolin (BD Biosciences, San Diego, CA, USA).
RESULTS
Identification of CAPN3 mutations
In the present study, we identified nine different CAPN3 mu-
tations in 13 patients from ten unrelated families. The nine 
CAPN3 mutations consisted of four missense, two small-inser-
F1 F2 F3a F3b F4 F5a F5b F5c
F6 F7 F8 F9 F10A
*
* * * * *
* * * * * * *
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
c.706G>A
NS
I II III IV
IS1 IS2
c.1524+1G>T†
c.1468C>T c.1789_1790insA†
c.1795dupA
c.2120A>G
c.2184+1G>T†
c.2384C>T†c.2050+1G>A
B
Fig. 1. Pedigrees and localizations of different CAPN3 mutations in Korean families with calpainopathy. (A) Pedigrees of 10 Korean families with 
CAPN3 mutations. Asterisks (*) indicate individuals whose DNA was used for sequencing. (B) Schematic representation of calpain 3 protein 
(NM_000070). Domain II is a cysteine protease domain, and domain IV is a calcium-binding domain. Muscle-specific sequences of calpain 3 at the N-
terminal domain I (NS), protease domain II (IS1), and between domains III and IV (IS2). Black dots (●), numbers of alleles with mutations; dagger (†), 
four novel mutations. 
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tion, and three splice-site mutations (Table 1), all of which were 
mainly located in domains III and IV (Fig. 1B). Five mutations 
were previously reported in the Leiden Database (http://www.
dmd.nl/capn3_home.html) or other reports.5,15,16 However, 
four mutations were not previously reported: c.1524+1G>T, 
c.1789_1790insA, c.2184+1G>T, and c.2384C>T. Among the 13 
patients, two CAPN3 mutations were identified in 11 patients 
from eight unrelated families (F1, F2, F3, F4, F5, F6, F7, and 
F8), and only one mutation was found in two patients from dif-
ferent families (F9 and F10). These two patients with a single 
mutation showed a total loss of calpain-3 protein via western 
blots (Fig. 2).
Clinical manifestations
The clinical spectra of 13 patients (4 men and 9 women) with 
CAPN3 mutations were summarized in Table 2. Family histo-
ry was positive in four families (F3, F5, F7, and F8). The medi-
an ages at examination and symptom onset were 33 (inter-
quartile range: 20–37) and 22 (interquartile range: 15–28), 
respectively. In 12 patients (none from F5), the first symptom 
was proximal muscle weakness, particularly in the lower ex-
tremities. Physical examination revealed joint contracture in 
nine patients, winged scapula in four, and lordosis in one. Calf 
pseudohypertrophy was identified in only the F1 patient. The 
median serum CK levels were 20-fold (interquartile range: 11- 
to 25-fold) above the upper limit of normal. Nerve conduction 
studies were normal, and needle electromyography revealed 
short duration, low-amplitude motor unit potentials, and an 
early recruitment pattern in all 13 patients. Electrocardiogra-
phy and echocardiography showed no evidence of cardiac 
Fig. 2. Calpain-3 band pattern on western blot. Western blot for cal-
pain-3 revealed normal expression in the F4 patient yet nearly total loss 
in six other patients.
Calpain-3
94 KDa
Actin
45 KDa
Patient No.  F4 F5b F6 F7 F8 F9 F10 Control
Table 2. Clinical and Laboratory Features of Thirteen Patients with CAPN3 Mutations
Mutation*
Sex/
age (yr)
Onset age (yr) Initial clinical diagnosis FH WS Contracture CK†
GMW 
scale
WB
F1
c.1795dupA/
  c.2120A>G
F/44 36 Muscular dystrophy  -  - Ankle 27 3 ND
F2
c.1795dupA/
  c.1795dupA
F/22 15 Muscular dystrophy  -  - Ankle 20 3 ND
F3a
c.2050+1G>A/
  c.1468C>T
F/35 23 Muscular dystrophy  +  + Ankle 58 7 ND
F3b
c.2050+1G>A/
  c.1468C>T
F/33 23 Muscular dystrophy  +  + Ankle 31 7 ND
F4
c.1789_1790insA/
  c.706G>A
F/16 12 Muscular dystrophy  -  + Ankle 20 4 +
F5a
c.2120A>G/
  c.2384C>T
F/42 25 Muscular dystrophy  +  - Ankle 6 8 ND
F5b
c.2120A>G/
  c.2384C>T
F/39 33 Muscular dystrophy  +  - Ankle 15 7 -
F5c
c.2120A>G/
  c.2384C>T
M/34 15 Muscular dystrophy  +  - Ankle 11 6 ND
F6
c.2120A>G/
  c.2120A>G
M/21 20 Polymyositis  -  - - 19 1 -
F7
c.1789_1790insA/
  c.1524+1G>T
F/19 8
Emery-Dreifuss muscular 
  dystrophy
 +  + Ankle, elbow 11 ND -
F8
c.1789_1790insA/
  c.2120A>G
M/19 16 HyperCKemia  +  - - 20 0 -
F9 c.2120A>G/? M/33 31 Polymyositis  -  - - ND 7 -
F10 c.2184+1G>T/? F/28 22 Muscular dystrophy  -  - - 3 6 -
FH, family history; WS, winged scapula; GMW scale, Gardner-Medwin and Walton scale; WB, Western blot; ND, no data.
*Mutation was assigned according to the CAPN3 (NM_000070) mRNA sequences, †Serum creatine kinase (CK) level is expressed as x-fold above the upper limit 
of the normal range.
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dysfunction in any tested patients.
Not only typical features of LGMD2A but also variable clinical 
features were found in the Korean patients with CAPN3 muta-
tions. In the F5 family, onset age ranged from 15 to 33 years, 
even though family members had the same mutations. Addi-
tionally, the F5a patient complained of a rapid deterioration in 
strength during pregnancy. She had four children and recalled a 
stepwise decline in muscle strength associated with pregnancy. 
The F7 patient was initially diagnosed with Emery-Dreifuss 
muscular dystrophy based on early prominent contractures of 
the elbow and ankle. The F8 patient and his older brother initial-
ly visited our hospital for elevated liver enzymes. However, a liv-
er biopsy was normal in his brother, and further laboratory stud-
ies showed elevated serum CK level. The patient and his brother 
did not show clinical signs such as muscle weakness, winged 
scapula, or ankle contracture. The F9 patient was initially diag-
nosed with polymyositis based on endomysial inflammatory 
cell infiltration and relatively abrupt clinical onset.
Pathological assessment
We analyzed muscle biopsies from nine patients in eight fami-
lies. The muscle specimens of six patients (F4, F5b, F6, F7, F9, 
and F10) showed nonspecific dystrophic features including 
varying degrees of fiber-size variability, increased endomysial 
fibrosis, and degenerative fibers. Among them, four patients 
(F5b, F7, F9, and F10) had lobulated fibers after staining with 
nicotinamide adenine dinucleotide tetrazolium reductase 
(Fig. 3), and the F6 patient had endomysial infiltration of a 
small number of inflammatory cells. However, three patients 
(F1, F5c, and F8) showed normal skeletal muscle histology. 
Muscle specimens were taken from the biceps brachii in F8 
and the vastus lateralis in F1 and F5c. When the muscle biop-
sy was performed, the F8 patient had no clinical symptoms; 
however, the F1 and F5c patients had mild weakness of the 
hip and shoulder girdle muscles. Western blot for calpain-3 
revealed normal expression in the F4 patient yet nearly total 
loss in six other patients (Fig. 2). In addition, immunohisto-
chemistry of the muscle specimens showed normal expression 
Fig. 3. Pathologic findings of F7 patients. (A) Fiber-size variation and increased endomysial fibrosis on hematoxylin and eosin staining. (B) A small 
number of degenerative muscle fibers (■) on modified Gomori trichrome staining. (C and D) A small number of lobulated fibers (*) after staining with 
nicotinamide adenine dinucleotide tetrazolium reductase. 
A
C
B
D
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of dystrophin, sarcoglycan (α, β, γ, and δ), dysferlin, α-dystro-
glycan, and caveolin in all 7 patients.
DISCUSSION
We analyzed the mutational, clinical, and pathological spectra 
of 13 Korean patients with calpainopathy. Among 13 patients, 
11 had genetically-confirmed calpainopathy, and two with only 
a single mutation were diagnosed based on an analysis of cal-
pain-3 protein.
As diagnostic tools for calpainopathy, both protein analysis 
and genetic tests are complex and require careful interpreta-
tion in the light of clinical findings.17 Western blots show nor-
mal or almost normal amounts of calpain-3 protein in about 
20–30% of patients with CAPN3 mutations.15,18,19 Additionally, 
protein loss of calpain-3 on western blots is not directly corre-
lated with clinical severity.18 In fact, normal expression of cal-
pain-3 protein was found in the F4 patient with two compound 
heterozygous mutations. Therefore, mutation analysis of CAPN3 
is the gold standard for the diagnosis of calpainopathy. How-
ever, previous reports demonstrated that only a single patho-
genic mutation is identified in about 10% of calpainopathy 
patients,2,15,17 as many CAPN3 mutations are located in a deep 
intronic position, which can be missed during routine gene se-
quencing.20 In our study, only one mutation was identified in 
F9 and F10 patients with complete loss of calpain-3 protein.
We studied the clinical and pathological features of Korean 
patients with calpainopathy. The first clinical symptom usual-
ly appeared in the first or second decade of life, and included 
proximal muscle weakness, winged scapula, and ankle con-
tracture. Half of the patients who received muscle biopsy had 
lobulated fibers. It is well-known that lobulated fibers increase 
as the disease progresses, although this is not a specific find-
ing in calpainopathy.16 However, highly variable features were 
also found in Korean calpainopathy patients. F1, F5b, and F9 
patients felt muscle weakness in the third decade. F7, F8, and 
F9 patients were initially diagnosed with Emery-Dreifuss mus-
cular dystrophy, hyperCKemia, and polymyositis, respective-
ly. Additionally, the F5a patient reported rapid deterioration 
of muscle and weakness in pregnancy. Although this was the 
first report on calpainopathy, one retrospective study reported 
permanent worsening in about half (54%) of 15 LGMD preg-
nancies.21 However, the cause of exacerbation during pregnan-
cy is not known. Three muscle specimens from patients in this 
study revealed normal skeletal muscle histology. A previous 
pathologic report showed normal findings in three preclinical 
biopsies except in one focal area of necrosis.22 In the present 
study, although F1 and F5c patients experienced mild weak-
ness of the hip and shoulder girdle muscles, muscle specimens 
of the vastus lateralis did not have pathologic abnormalities. 
This result was likely due to the following reasons. Firstly, the 
predominantly affected muscles in ambulatory patients with 
calpainopathy are in the posterior compartment of the thigh.23 
Secondly, the muscle specimens showed that necrotic and re-
generating fibers tended to occur in clusters.16 
We did not find a correlation between genotype and pheno-
type in Korean patients with calpainopathy. It is known that 
null mutations are usually associated with a more severe phe-
notype than missense mutations.3,15,24,25 In our study, the F7 
patient with two null mutations showed severe phenotype, in-
cluding early clinical onset and prominent joint contracture. 
However, the F2 patient with two null mutations did not show 
a more severe phenotype than other patients with missense 
mutations. In addition, affected members of the F5 family 
showed clinical variability including onset age, despite the 
family members having the same genotype. 
The present study suggests the possibility of a relatively low 
incidence of calpainopathy in Korea compared to other coun-
tries. To date, our institute, one of the largest myology centers in 
Korea, has genetically confirmed DYSF mutations, a genetic 
cause of LGMD2B, in 45 patients (unpublished data). On the 
other hand, the present study identified CAPN3 mutations in 
only nine of 51 tested patients with suspicious calpainopathy. 
However, the relatively small number of patients limited the in-
terpretability of the present study. Therefore, further studies are 
needed to identify the clinical and mutational findings in a lar-
ger cohort. 
In conclusion, we identified nine different mutations in-
cluding four novel CAPN3 mutations in Korean patients. The 
present study confirmed the high variability of clinical and 
pathological features in Koreans with calpainopathy.
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